Successfully concluded at Shanghai New International Expo Centre (SNIEC) on June 20, 2019, CPhI & P-MEC China 2019 achieved its goals of displaying new achievements, igniting collision of new ideas, and out-looking on new trends in the three days and received high attention from global pharmaceutical industry professionals.
Closing its doors at the Shanghai New International Expo Centre (SNIEC) on June 20, 2019, CPhI & P-MEC China celebrated yet another successful event following three days during which it presented the latest industry innovations and trend forecasts, while fuelling collaboration in the industry.
New records set after 19 years of history
Hosted by Informa Markets and the China Chamber of Commerce for Import & Export of Medicines & Health Products (CCCMHPIE) the event was co-sponsored by Sinoexpo Informa Markets and held its 19th edition this year. Since its first edition took place in 2001, CPhI & P-MEC China has become Asia’s largest and most specialised pharmaceutical event. Throughout the years, the event has witnessed the country’s pharmaceutical industry progress from playing catch-up with the rest of the world to leading the way. 2019’s edition saw new records set in terms of scale as well as the number of exhibitors and visitors at the event. This year’s exhibition area exceeded 200,000m2 - covering all 17 halls of the SNIEC - while exhibitor numbers reached 3,246 and the total visitor number from both domestic and overseas visitors reached 66,569 – a 10% increase on 2018’s figures. The event also saw a 32% increase in overseas visitors reaching 20,302. There was an endless stream of both Chinese and international traders going to stands onsite to negotiate, contributing to an unprecedentedly grand occasion.
Developing new patterns of industry transformation and upgrading
With Healthy China leading an initiative to put an increased focus on China’s medical reform, the nation’s pharmaceutical industry is undergoing a golden period of development. Since the implementation of new policies, Chinese pharmaceuticals are focusing on quality and innovation including the generic drug consistency evaluation, acceleration of pharmaceutical product review and approval, and the Marketing Authorization Holders system. Chinese pharmaceutical practitioners are also promoting development opportunities.
CPhI & P-MEC China, a world-leading one-stop vertical trade and exchange event of the pharmaceutical industry, has been promoting industry development, based on the orientation of focusing, cultivating, and innovating. 13 zones including APIs, fine chemicals and intermediates, pharmaceutical excipients, finished dosages, CMO & CRO, biopharmaceuticals, natural extracts, animal health and feed, pharmaceutical machinery, packaging materials, laboratory instruments, environmental protection & clean technology, and pharmaceutical logistics were covered in this session which set up a two-way platform for pharmaceutical enterprises to optimize the industrial chain layout and accelerate transformation and innovation for the deep involvement of Chinese and overseas visitors.
Each zone manifested sparkling highlights in 2019: PharmaExcipients China teamed up with FDF China to gather more than 100 prominent Chinese and international pharmaceutical excipients and preparations manufacturers, who showcased their innovative products and technologies; NEX China led nearly 400 natural extract enterprises who came together to share quality resources to incite innovation in the natural extract industry and to launch a new era of the health industry; the high-profile bioLIVE China focused on the latest policies, market strategies, technological development, clinical studies, and patent strategies of the Chinese biopharmaceutical industry and look closely at the R&D trends and global dynamics of biological drugs; ICSE China joined hands with Chinese and overseas CDMOs, CROs, and CMOs to bring first-class contract development and ma...
(All Rights Reserved)